103 related articles for article (PubMed ID: 9532615)
1. Antiprogestin-mediated inactivation of cytochrome P450 3A4.
Jang GR; Benet LZ
Pharmacology; 1998 Mar; 56(3):150-7. PubMed ID: 9532615
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
3. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes.
Jang GR; Wrighton SA; Benet LZ
Biochem Pharmacol; 1996 Sep; 52(5):753-61. PubMed ID: 8765473
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone.
Jang GR; Benet LZ
Drug Metab Dispos; 1997 Oct; 25(10):1119-22. PubMed ID: 9321513
[TBL] [Abstract][Full Text] [Related]
5. Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.
Jang GR; Benet LZ
J Pharmacokinet Biopharm; 1997 Dec; 25(6):647-72. PubMed ID: 9697076
[TBL] [Abstract][Full Text] [Related]
6. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based inhibition of rat liver microsomal diazepam C3-hydroxylase by mifepristone associated with loss of spectrally detectable cytochrome P450.
Reilly PE; Gomi RJ; Mason SR
Chem Biol Interact; 1999 Mar; 118(1):39-49. PubMed ID: 10227577
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactions.
Hutzler JM; Melton RJ; Rumsey JM; Schnute ME; Locuson CW; Wienkers LC
Chem Res Toxicol; 2006 Dec; 19(12):1650-9. PubMed ID: 17173379
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.
Dao B; Vanage G; Li XJ; Bardin CW; Koide SS
Contraception; 1997 Jan; 55(1):35-40. PubMed ID: 9013059
[TBL] [Abstract][Full Text] [Related]
11. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
J Pharmacol Exp Ther; 1999 Jul; 290(1):429-38. PubMed ID: 10381809
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system.
Haehner T; Refaie MO; Müller-Enoch D
Arzneimittelforschung; 2004; 54(1):78-83. PubMed ID: 14979613
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.
Lightning LK; Jones JP; Friedberg T; Pritchard MP; Shou M; Rushmore TH; Trager WF
Biochemistry; 2000 Apr; 39(15):4276-87. PubMed ID: 10757976
[TBL] [Abstract][Full Text] [Related]
17. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4.
Khan KK; He YQ; Correia MA; Halpert JR
Drug Metab Dispos; 2002 Sep; 30(9):985-90. PubMed ID: 12167563
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
Jacobson PA; Green K; Birnbaum A; Remmel RP
Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
[TBL] [Abstract][Full Text] [Related]
19. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
Bu HZ; Magis L; Knuth K; Teitelbaum P
Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.
Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K
J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
